Safety and Performance Study to Evaluate Access to Pulmonary Veins for Treatment of Paroxysmal AF

NCT ID: NCT02521896

Last Updated: 2015-08-13

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 8 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2014-08-31
• Study Completion Date: 2015-01-31

Brief Summary

The study is intended to assess the safety and performance of the Vado™ Steerable Sheath in facilitating ease of access to the pulmonary veins (PV) for the treatment of paroxysmal atrial fibrillation and persistent atrial fibrillation (AF). The study will be a prospective, single-center, non-randomized investigation.

Detailed Description

The design for this study involves the sequential enrollment of patients with documented paroxysmal atrial fibrillation who have had two (2) or more AF episodes for at least 30 seconds in length within six (6) months prior to enrollment. Target population shall be selected from the treatable AF population that meets both inclusion/exclusion criteria.It is intended that the Vado Steerable Sheath will be used as part of standard clinical workflow procedures, with no procedural deviations relative to other procedures requiring steerable sheaths. Individual subjects will be studied during mapping and ablation procedures and followed until release from hospital post procedure per institutional standard of care.

Conditions

Atrial Fibrillation

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Steerable sheath for intracardiac access

Vado Steerable sheath system consisting of a dilator and steerable sheath for left atrial access, positioning of ablation catheters and placement of mapping and ablation catheters for circumferential ablation

Group Type: EXPERIMENTAL

Steerable Sheath System

Intervention Type: DEVICE

The Vado™ Steerable Sheath consists of a dilator and steerable sheath which are designed to provide intracardiac access and flexible catheter positioning in the cardiac anatomy.

Interventions

Steerable Sheath System

The Vado™ Steerable Sheath consists of a dilator and steerable sheath which are designed to provide intracardiac access and flexible catheter positioning in the cardiac anatomy.

Intervention Type: DEVICE

Other Intervention Names

Vado Steerable Sheath

Eligibility Criteria

Inclusion Criteria

• suitable candidate for intra-cardiac mapping for arrhythmias with documented PAF defined by HRS Criteria.
• Eighteen to Eighty years of age
• Signed informed consent

Exclusion Criteria

• Intracardiac thrombus, tumor or other abnormality that precludes catheter introduction and placement
• Severe cerebrovascular disease or history of cerebrovascular event within one (1) month
• Patients with severely impaired kidney function as measured by a Cockcroft-Gault Glomerular Filtration Rate (GFR) 3 with a GFR < 29.
• Active gastrointestinal bleeding, infection or fever (> 100.5/38C)
• Severe co morbidity or Short life expectancy (<1 year) due to other illnesses such as cancer, pulmonary, hepatic or renal disease
• Structural heart disease of clinical significance including

• Symptoms of congestive heart failure including, but not limited to, NYHA Class III or IV CHF and/or documented ejection fraction < 40% measured by acceptable cardiac testing
• Stable/unstable angina or ongoing myocardial ischemia
• Myocardial infarction (MI) within three months of enrollment
• Aortic or mitral valve disease > Grade II
• Congenital heart disease (not including ASD or PFO without a right to left shunt) where the underlying abnormality increases the risk of an ablative procedure
• Enrollment in any other ongoing arrhythmia study protocol
• Any ventricular tachyarrhythmia currently being treated where the arrhythmia or the management may interfere with this study
• Active infection or sepsis
• Female patient is pregnant or lactating
• Untreatable allergy to contrast media
• Any diagnosis of atrial fibrillation secondary to electrolyte imbalance, thyroid disease, or any other reversible or non-cardiovascular causes
• History of blood clotting (bleeding or thrombotic) abnormalities
• Known sensitivities to heparin or warfarin
• Severe COPD (identified by an FEV1 <1)

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Kalila Medical

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Ian Crozier, MD

Role: PRINCIPAL_INVESTIGATOR

Christchurch Hospital

Matthew Daly, MD

Role: PRINCIPAL_INVESTIGATOR

Christchurch Hospital

References

Piorkowski C, Eitel C, Rolf S, Bode K, Sommer P, Gaspar T, Kircher S, Wetzel U, Parwani AS, Boldt LH, Mende M, Bollmann A, Husser D, Dagres N, Esato M, Arya A, Haverkamp W, Hindricks G. Steerable versus nonsteerable sheath technology in atrial fibrillation ablation: a prospective, randomized study. Circ Arrhythm Electrophysiol. 2011 Apr;4(2):157-65. doi: 10.1161/CIRCEP.110.957761. Epub 2011 Jan 19.

Reference Type: BACKGROUND

PMID: 21248246 (View on PubMed)

Other Identifiers

CP1-001

Identifier Type: -

Identifier Source: org_study_id